reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Storage and handling follow conventional peptide practice. Lyophilized epitalon is typically kept refrigerated or frozen, protected from moisture and light, and allowed to equilibrate to room temperature before opening to avoid condensation. Once dissolved, aqueous solutions are usually stored cold and used within a short period, since dilute peptide solutions can support microbial growth and may slowly degrade. The absence of cysteine and methionine reduces, but does not eliminate, oxidation concerns during long-term storage.
Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.
Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | RP-HPLC | Reported as percent area, often ≥95% |
| Identity confirmation | Mass spectrometry | Observed mass compared with ~390 Da |
| Typical storage temperature | -20 °C or below | Lyophilized powder, desiccated |
| Reconstitution solvent | Sterile water or buffer | Acidic residues aid dissolution |
| Common synonyms | AEDG; epithalon | Spelling varies in literature |
Reversed-phase high-performance liquid chromatography is the standard approach for assessing purity, usually with ultraviolet detection near 214 nm, where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the molecular mass and helps reveal truncation or deletion byproducts. Amino acid analysis can verify composition, and counterion content is sometimes measured because peptides purified with trifluoroacetic acid retain variable amounts of that salt. Purity figures reported without a stated method and detection wavelength are difficult to interpret.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Type I : Extra-dural; no nerve roots or rootlets such as intra-sacral meningoceles; probably of congenital origin developing from the dural sac to which they are connected by a little collar. They are found at the point of exit of a dorsal nerve root from the dural sac. They are sometimes difficult to identify and can be "seen" as a type II cyst on imaging. These cysts are often associated with foramina enlargement and scalloping of the vertebrae. It is very important to distinguish them from sacral meningoceles going to the pelvic area; they are often associated with other congenital abnormalities (teratomes, dermoïdes, lipomas, and other abnormalities(uro-genital and ano-rectal)) Type II: Extra-dural; nerve root present (such as Tarlov or perineural cysts). There are often not only one but multiple cysts, mostly found in the sacrum area. There are two types: Tarlov (perineural) cysts are located posteriorly to the root ganglion, with nerve fibres inside or nerve tissue in the walls; they are not communicating with the perineural arachnoid space. Type-II cysts are very small in the upper sacral area, but can be bigger (up to 3 centimetres or 1.2 inches) if found located in the lower part of the sacrum. The second variant of type-II cysts are called "meningeal diverticula". They are located anteriorly to the nerve root ganglion, with nerves fibres inside and communicating with the subarachnoid space. Type III: intra-dural; these are either congenital or caused by trauma; they are rarely associated with other abnormalities and rare in occurrence.
== Neurotransmitter systems == Neurons expressing certain types of neurotransmitters sometimes form distinct systems, where activation of the system affects large volumes of the brain, called volume transmission. Major neurotransmitter systems include the noradrenaline (norepinephrine) system, the dopamine system, the serotonin system, and the cholinergic system, among others. Trace amines have a modulatory effect on neurotransmission in monoamine pathways (i.e., dopamine, norepinephrine, and serotonin pathways) throughout the brain via signaling through trace amine-associated receptor 1. A brief comparison of these systems follows:
Turin developed as a Fordist city in the early 20th century, which meant a shift from a service-based economy to an industry-based one. In the vein of many Fordist economies Turin's economy relies heavily upon its automotive and aerospace industries. Despite the general decline of the automotive industry since the oil crisis of 1973, the city still relies heavily upon its automotive industry. Since before the Second World War, the automotive industry has been the largest employer in the city, and almost all exports from Turin are manufactured goods. The city serves as the headquarters to Fiat (Fabbrica Italiana Automobili Torino; Turin Italian Automobiles Factory), which has since been absorbed by its parent company, the Fiat Chrysler Automobiles group (now Stellantis) headquartered in Amsterdam, the eighth largest automotive company in the world. Turin is still home to a sizeable Fiat factory. From the 1980s, Turin diversified its economy and is shifting back towards a service economy. Tech and innovation industries are booming in Turin, which was ranked third in number of innovative startups and firms in the information-tech sector, and has some of the most patent applications to the European Patent Office of any city. In 2008 the city generated a GDP of $68 billion, ranking as the world's 78th richest city by purchasing power, and 16th in Europe, according to PricewaterhouseCoopers. Turin accounts for 8 percent of Italy's GDP. The city has been ranked in 2010 by Globalization and World Cities Research Network as a Gamma-level city.
=== 18 December === The Russian government recruited musicians to boost morale. The so-called "front-line creative brigade" was to be made up from mobilised soldiers and musicians who have volunteered.
Sources: en.wikipedia.org
=== N05AA Phenothiazines with aliphatic side-chain === N05AA01 Chlorpromazine N05AA02 Levomepromazine N05AA03 Promazine N05AA04 Acepromazine N05AA05 Triflupromazine N05AA06 Cyamemazine N05AA07 Chlorproethazine
== Adverse effects == Adverse effects of 5-MAPB are similar to those of MDMA and may include dehydration and hyperthermia, among others. It may also cause serotonergic neurotoxicity like MDMA. There have been cases of hospitalization and death in association with 5-MAPB.
Annual per capita consumption of cheese was 4 pounds (1.8 kg) in 1909; 32 pounds (15 kg) in 2000; the average person consumed 389 grams (13.7 oz) of carbohydrates daily in 1970; 490 grams (17 oz) in 2000; 41 pounds (19 kg) of fats and oils in 1909; 79 pounds (36 kg) in 2000. In 1977, 18% of an average person's food was consumed outside the home; in 1996, this had risen to 32%. Obesity is a major public health problem in the United States owing to its rapidly increasing prevalence, substantial mortality and morbidity, and growing healthcare costs. Several studies have inquired about the relationship between community food environment and obesity, which are often inversely related. The large-scale study demonstrated a substantial and inverse relationship between the local food environment and adult obesity in the US using local spatially weighted regression. Approximately 23.5 million American live in food deserts, areas in geolocations with minimal healthy food retailers. More importantly, there were considerable regional differences in the strength and direction of this connection. The findings of the study also show the need for geographically specific public health policies and interventions to address issues with food environments that are specific to particular regions.
Sources: en.wikipedia.org
Beginning in the 11th century, European soldiers and knights relied on chain mail for protection of their bodies, and chain armor "shirts" with wide sleeves that hung to the elbow were common. However, it wasn't until the 12th century that chain mail shirts with longer, narrower sleeves began to be worn, and these on occasion had chain mail mittens or "muffs" resembling fingerless gloves and with a pocket for the thumb (though some of these did have complete fingers as well). These attached at the lower edge of the sleeve, and protected the wearer's hands from cuts and lacerations during combat but offered no protection against crushing blows. It wasn't until the early 14th century that armorers began to design fully articulated plate armor: along with this development of the use of plates as a means of protecting the body from blows was the development of hand protection in the form of gauntlets made of overlapping plates of steel. These were created both in the fingerless "mitten" style (which offered plate armor protection and allowed the fingers to share heat but limited the wearer's ability to move those fingers) as well as the fully fingered "glove" style (which though still ungainly and less comfortable in cold weather, permitted full use of all of the fingers). A variety of gauntlet called a "demi-gauntlet" or "demi-gaunt" also came into use around this time. A demi-gaunt is a type of plate armour gauntlet that only protects the back of the hand and the wrist: demi-gaunts are worn with gloves made from chain mail or padded leather.
=== No development reported === AF-130 – purinergic P2X3 receptor antagonist – migraine [40] B-244 (AOB-101; AOB-102; AOB-103; AOB-201; AOB-202; AOB-203; B244; nitrosomonas eutropha D23) – bacteria replacement – migraine [41] Carabersat (SB-204269) – undefined mechanism of action (anticonvulsant) – migraine [42] CLE-500 – undefined mechanism of action – cluster headache [43] CT-044 analogues - CERSCI Therapeutics – reactive oxygen species (ROS) inhibitor – migraine [44] Cyclobenzaprine extended release (Amrix; Bonelax; EUR-1002) – tricyclic antidepressant (non-selective monoamine reuptake inhibitor and receptor modulator and other actions) – migraine [45] Donepezil (Allydone; Aricept; E-2020; E-2022; Eranz) – acetylcholinesterase inhibitor – migraine [46] Donitriptan mesilate (F-12640) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [47] Estetrol (E4; Donesta) – estrogen (estrogen receptor agonist) – migraine [48] Filorexant (MK-6096) – orexin OX1 and OX2 receptor antagonist – migraine [49] Flunarizine (XEN-007) – calcium channel blocker, non-selective monoamine receptor modulator, other actions – migraine [50] Ibudilast (AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos) – phosphodiesterase PDE4 inhibitor – headache [51] IPX-232 – undefined mechanism of action – migraine [52] Ketamine hydrochloride intranasal – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – cluster headache [53] Ondansetron/rizatriptan – oral transmucosal film (rizatriptan/ondansetron; MSRX-202) – combination of ondansetron (serotonin 5-HT3 receptor antagonist and antiemetic) and rizatriptan (triptan) [54] Oxytocin (TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist – headache [55] Piroxicam betadex (β-cyclodextrin piroxicam; Brexecam; Brexidol; Brexin; Brexine; Brexinil; CHF 1194; Cicladol; Cycladol; Flogene; piroxicam β-cyclodextrin) – COX inhibitor/NSAID – migraine, tension-type headache [56] Psilocybin (low-dose psilocybin; BPL-PSILO) – non-selective serotonin receptor agonist and psychedelic hallucinogen – headache [57] Psilocybin (MYCO-001; MYCO-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – headache [58] Psilocybin (SYNP-101; synthetic psilocybin) – non-selective serotonin receptor agonist and psychedelic hallucinogen – cluster headache, migraine [59] Relutrigine (PRAX-562) – sodium channel blocker – headache [60] Research programme: calcitonin gene-related peptide receptor antagonists - Merck (CGRP receptor antagonists; Imidazoazepanes; MK-2918; MK-8825) – calcitonin gene-related peptide receptor (CGRPR) antagonists [61] Research programme: GPCR modulators - Nxera Pharma – various actions [62] Research programme: migraine and pain therapeutics - NeurAxon – various actions – migraine [63] Research programme: pain and migraine therapy - OptiNose (OPT-1005) – undefined mechanism of action – migraine [64] Rizatriptan intranasal – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [65] Rizatriptan oral film – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [66] Salubrin (PH80; PH-80; ORG-39479) – vomeropherine – migraine [67] [68] Sumatriptan (Imigran Nasal Spray; Imitrex Nasal Spray) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – menstrual migraine [69] Sumatriptan transmucosal (Omexa) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [70] Zucapsaicin (cis-capsaicin; Civamide; Civanex; Dolorac; Neuroderm; Zuacta) – transient receptor potential cation channel subfamily V member 1 (TRPV1) agonist – cluster headache, migraine [71]
== External links == Gerritsen VB (September 2003). "The Plant Kingdom's sloth". Protein Spotlight. Swiss Institute of Bioinformatics (SIB). Rubisco plods along at a mere three molecules per second... To bypass such slothfulness, plants synthesize a gross amount of Rubisco, sometimes up to 50% of their total protein content!
Sources: en.wikipedia.org
Identity is normally confirmed by mass spectrometry, which checks the measured mass against the expected value near 390 daltons. Reverse-phase high-performance liquid chromatography is used alongside it to assess purity. Amino acid analysis can provide additional composition data.
The powder is generally kept refrigerated or frozen, protected from light and moisture. Vials should reach room temperature before opening to prevent condensation. Reconstituted solutions are usually stored cold and used within a limited window because dilute solutions can degrade or support microbial growth.
Epitalon is not an approved drug in major Western regulatory jurisdictions. Its legal status differs between countries, and it is often distributed as a research chemical. This means product documentation and purity vary considerably between suppliers.
The usual approach is reversed-phase HPLC with ultraviolet detection, reported as a percentage of total peak area. Mass spectrometry is used alongside chromatography to confirm identity rather than purity alone.